Comparing Health Economic Models to Answer Public Health Problems: A Review
暂无分享,去创建一个
[1] B. Detournay,et al. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer , 2010, International Journal of Public Health.
[2] A. Chuck. Cost-effectiveness of 21 alternative cervical cancer screening strategies. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] Adalsteinn D. Brown,et al. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. , 1999, JAMA.
[4] J. Salomon,et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. , 2008, Journal of the National Cancer Institute.
[5] J. Lew,et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. , 2017, The Lancet. Public health.
[6] L. Cameron,et al. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. , 2013, The Journal of infection.
[7] T. Blakely,et al. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. , 2016, Population health metrics.
[8] A. Detsky,et al. A clinician's guide to cost-effectiveness analysis. , 1990, Annals of internal medicine.
[9] Chang Ar. The cervical smear test in the next millennium. , 1999, Hong Kong medical journal = Xianggang yi xue za zhi.
[10] S. Wacholder,et al. Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.
[11] Karl Claxton,et al. Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.
[12] David J. Pannell,et al. Sensitivity Analysis of Normative Economic Models: Theoretical Framework and Practical Strategies , 1997 .
[13] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[14] Mark Schiffman,et al. The promise of global cervical-cancer prevention. , 2005, The New England journal of medicine.
[15] Shalini L Kulasingam,et al. Screening for Cervical Cancer: A Modeling Study for the US Preventive Services Task Force , 2013, Journal of lower genital tract disease.
[16] P. Tappenden,et al. Methodological issues in the economic analysis of cancer treatments. , 2006, European journal of cancer.
[17] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] T. Wright,et al. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. , 2005, Journal of the National Cancer Institute.
[19] G. Sanders,et al. Decision science and cervical cancer , 2003, Cancer.
[20] M. García-Molina,et al. Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. , 2008, Salud publica de Mexico.
[21] J. Chahoud,et al. Wealth, Health Expenditure, and Cancer: A National Perspective. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[22] M. Jit,et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. , 2014, Vaccine.
[23] M. Jit,et al. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model , 2015, BMJ : British Medical Journal.
[24] Bernhard Gibis,et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. , 2006, European journal of public health.
[25] I. Morhason-Bello,et al. Modeling optimal cervical cancer prevention strategies in Nigeria , 2014, BMC Cancer.
[26] N. Muñoz,et al. Human papillomavirus and cancer: the epidemiological evidence. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[27] E. Weiderpass,et al. A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[28] Y. Qiao,et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study , 2011, BMC Cancer.
[29] Mark Jit,et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. , 2014, The Lancet. Global health.
[30] Karen M Kuntz,et al. Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.
[31] Jane J. Kim,et al. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway , 2012, British Journal of Cancer.
[32] K. Howard,et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years , 2010, BMC public health.
[33] Douglas K Owens,et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials , 1996, The Lancet.
[34] Paul C Langley. Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[35] J. Habbema,et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. , 2002, Journal of the National Cancer Institute.
[36] Y. Taketani,et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost‐effectiveness analysis , 2012, BJOG : an international journal of obstetrics and gynaecology.
[37] W. Lawrence,et al. Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.
[38] Thomas Faunce,et al. Decision-analytical modelling in health-care economic evaluations , 2008, The European Journal of Health Economics.
[39] Mark S Roberts,et al. Simulation and critical care modeling , 2004, Current opinion in critical care.
[40] M. Shanahan,et al. The cost‐effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? , 2008, Australian and New Zealand journal of public health.
[41] Jeremy D Goldhaber-Fiebert,et al. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. , 2006, Vaccine.
[42] S. Goldie,et al. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. , 2008, Vaccine.
[43] S. You,et al. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system , 2010, British Journal of Cancer.
[44] De Kok. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings : cost effectiveness analysis based on a Dutch microsimulation model , 2017 .
[45] S. Kulasingam,et al. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis , 2009, BMC medicine.
[46] J. Peto,et al. The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.
[47] Tze-Yun Leong,et al. Multiple Perspective Dynamic Decision Making , 1998, Artif. Intell..
[48] Robert L Harrison,et al. Introduction To Monte Carlo Simulation. , 2010, AIP conference proceedings.
[49] Stavros Petrou,et al. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.
[50] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[51] V Beral,et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study , 2004, British Journal of Cancer.
[52] A. Farnsworth. Screening for the Prevention of Cervical Cancer in the Era of Human Papillomavirus Vaccination: An Australian Perspective , 2011, Acta Cytologica.
[53] Jonathan Karnon,et al. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.
[54] E. Weiderpass,et al. Priority Setting for Improvement of Cervical Cancer Prevention in Iran. , 2015, International journal of health policy and management.
[55] Sue J Goldie,et al. Cost-effectiveness of cervical-cancer screening in five developing countries. , 2005, The New England journal of medicine.
[56] Graham A. Colditz,et al. Cost-effectiveness of screening for colorectal cancer in the general population. , 2000, JAMA.
[57] J. Dillner,et al. Cost‐effectiveness of primary cytology and HPV DNA cervical screening , 2008, International journal of cancer.
[58] S Gallivan,et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.
[59] Y. Qiao,et al. Cost‐effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high‐risk region of China , 2010, International journal of cancer.
[60] B E Hillner,et al. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. , 1991, The New England journal of medicine.
[61] T. Wright,et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. , 2001, JAMA.
[62] J. Habbema,et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. , 1997, British Journal of Cancer.
[63] Evan R. Myers,et al. Cost-Effectiveness Analysis of Liquid-Based Cytology and Human Papillomavirus Testing in Cervical Cancer Screening , 2006, Obstetrics and gynecology.
[64] W. Lawrence,et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. , 2002, Journal of the National Cancer Institute.
[65] T. Wright,et al. Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More , 2004, Obstetrics and gynecology.
[66] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[67] G. Dreyer,et al. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. , 2009, Gynecologic oncology.
[68] K. Goodman,et al. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. , 2010, Gynecologic oncology.
[69] J. Salomon,et al. Cost-effectiveness of Rotavirus vaccination in Vietnam , 2009, BMC public health.
[70] John Eng,et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. , 2003, JAMA.
[71] Sally C. Brailsford,et al. A comparison of discrete event simulation and system dynamics for modelling health care systems , 2001 .
[72] T. Chen,et al. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. , 2006, Journal of medical screening.
[73] A. Mrhar,et al. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. , 2010, European journal of public health.
[74] A. Nahvijou,et al. Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer , 2016, PloS one.
[75] E. Myers,et al. Costs and Effectiveness of Alternative Strategies for Cervical Cancer Screening in Military Beneficiaries , 2002, Obstetrics and gynecology.
[76] J. Berkhof,et al. The health and economic effects of HPV DNA screening in The Netherlands , 2010, International journal of cancer.